[1]
Cohen H, Mackie IJ, Devreese KMJ, International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies. Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey. Journal of thrombosis and haemostasis : JTH. 2019 Oct:17(10):1715-1732. doi: 10.1111/jth.14560. Epub 2019 Aug 1
[PubMed PMID: 31271706]
Level 3 (low-level) evidence
[2]
Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. American journal of hematology. 2012 May:87 Suppl 1(Suppl 1):S75-81. doi: 10.1002/ajh.23196. Epub 2012 Mar 31
[PubMed PMID: 22473619]
[3]
Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of thrombosis and haemostasis : JTH. 2020 Jul:18(7):1569-1575. doi: 10.1111/jth.14846. Epub
[PubMed PMID: 32619349]
[4]
Tripodi A, Scalambrino E, Clerici M, Peyvandi F. Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients. Biomedicines. 2023 Jun 19:11(6):. doi: 10.3390/biomedicines11061760. Epub 2023 Jun 19
[PubMed PMID: 37371855]
[5]
Devreese KMJ, Zuily S, Meroni PL. Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of translational autoimmunity. 2021:4():100134. doi: 10.1016/j.jtauto.2021.100134. Epub 2021 Nov 6
[PubMed PMID: 34816113]
[6]
Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Research and practice in thrombosis and haemostasis. 2022 Feb:6(2):e12676. doi: 10.1002/rth2.12676. Epub 2022 Mar 15
[PubMed PMID: 35316943]
[7]
Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clinical chemistry. 2003 Oct:49(10):1608-14
[PubMed PMID: 14500585]
Level 3 (low-level) evidence
[8]
Heikal N, Martins TB, White SK, Willis R, Ware Branch D, Schmidt RL, Tebo AE. Laboratory Evaluation of Antiphospholipid Syndrome. American journal of clinical pathology. 2019 Oct 7:152(5):638-646. doi: 10.1093/ajcp/aqz085. Epub
[PubMed PMID: 31305881]
[9]
Apipongrat D, Lamool R, Arnutti P, Ruangpratheep C, Chantkran W. Comparison of different algorithms for lupus anticoagulant detection: a single-center experience. Research and practice in thrombosis and haemostasis. 2024 Jan:8(1):102333. doi: 10.1016/j.rpth.2024.102333. Epub 2024 Jan 30
[PubMed PMID: 38404944]
[10]
Petri MA, Avci M, Magder LS. Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. Lupus science & medicine. 2020 Nov:7(1):. doi: 10.1136/lupus-2020-000406. Epub
[PubMed PMID: 33139453]
[11]
Capozzi A, Manganelli V, Riitano G, Recalchi S, Truglia S, Alessandri C, Longo A, Garofalo T, Misasi R, Valesini G, Conti F, Sorice M. Tissue factor over-expression in platelets of patients with anti-phospholipid syndrome: induction role of anti-β2-GPI antibodies. Clinical and experimental immunology. 2019 Apr:196(1):59-66. doi: 10.1111/cei.13248. Epub 2019 Jan 15
[PubMed PMID: 30549270]
[12]
Park SH, Jang S, Park CJ, Chi HS. Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful? BioMed research international. 2016:2016():2641526. doi: 10.1155/2016/2641526. Epub 2016 Aug 17
[PubMed PMID: 27610369]
[13]
Kempers EK, Dalm VASH, van Rijn MJE, Mulders AGMGJ, Leebeek FWG, de Maat MPM, Jansen AJG. Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice. Rheumatology advances in practice. 2021:5(3):rkab093. doi: 10.1093/rap/rkab093. Epub 2021 Nov 27
[PubMed PMID: 34917873]
Level 3 (low-level) evidence
[14]
Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clinical chemistry. 2007 Sep:53(9):1629-35
[PubMed PMID: 17712001]
[15]
Magnette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thrombosis journal. 2016:14():49. doi: 10.1186/s12959-016-0123-z. Epub 2016 Dec 12
[PubMed PMID: 27999475]
[16]
Pappas AA, Palmer SK, Meece D, Fink LM. Rapid preparation of plasma for coagulation testing. Archives of pathology & laboratory medicine. 1991 Aug:115(8):816-7
[PubMed PMID: 1863193]
[17]
Molinari AC, Martini T, Banov L, Ierardi A, Leotta M, Strangio A, Santoro RC. Lupus Anticoagulant Detection under the Magnifying Glass. Journal of clinical medicine. 2023 Oct 20:12(20):. doi: 10.3390/jcm12206654. Epub 2023 Oct 20
[PubMed PMID: 37892792]
[18]
Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ (Clinical research ed.). 2023 Feb 27:380():e069717. doi: 10.1136/bmj-2021-069717. Epub 2023 Feb 27
[PubMed PMID: 36849186]
Level 3 (low-level) evidence
[19]
Tripodi A. Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant. Biomedicines. 2021 Jul 20:9(7):. doi: 10.3390/biomedicines9070844. Epub 2021 Jul 20
[PubMed PMID: 34356908]
[20]
Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L, Sivapalaratnam S, Pasi KJ, MacCallum P. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. The New England journal of medicine. 2020 Jul 16:383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5
[PubMed PMID: 32369280]
[21]
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.). 2019 Sep:71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6
[PubMed PMID: 31385462]
[22]
Quehenberger P, Wagner O. [Laboratory diagnosis of the lupus anticoagulants]. Hamostaseologie. 2005 Feb:25(1):50-4
[PubMed PMID: 15711720]
[23]
Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, Ichikawa K, Sturgess A, Krilis SA. Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. Clinical and experimental immunology. 2001 Jun:124(3):502-8
[PubMed PMID: 11472415]
[24]
Reshetnyak T, Cheldieva F, Cherkasova M, Lila A, Nasonov E. IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. International journal of molecular sciences. 2022 Aug 21:23(16):. doi: 10.3390/ijms23169432. Epub 2022 Aug 21
[PubMed PMID: 36012697]
[25]
Pengo V, Bison E, Banzato A, Zoppellaro G, Jose SP, Denas G. Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT). Methods in molecular biology (Clifton, N.J.). 2017:1646():169-176. doi: 10.1007/978-1-4939-7196-1_14. Epub
[PubMed PMID: 28804828]
[26]
Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. Journal of autoimmunity. 2000 Sep:15(2):173-8
[PubMed PMID: 10968905]
[27]
Smit B, Hudig F, Venhuizen JH, Haitjema S, Limper M, Urbanus R, Huisman A. Routine Lupus Anticoagulant Sensitive aPTT Testing Can Prevent Unnecessary LA Testing. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2023 Jan-Dec:29():10760296231183427. doi: 10.1177/10760296231183427. Epub
[PubMed PMID: 37322895]
[28]
Sun H, Yang S, Li P, Shang X, Wang P, Zhang J, Yuan L, Yin R, Gao N, Zhao J. Comparative Assessment of APTT Reagents for Evaluating Anticoagulant Sensitivity of Fucosylated Glycosaminoglycans (FGs) Derived from Sea Cucumbers. Marine drugs. 2023 Oct 29:21(11):. doi: 10.3390/md21110568. Epub 2023 Oct 29
[PubMed PMID: 37999392]
Level 2 (mid-level) evidence
[29]
Santoro RC, Molinari AC, Leotta M, Martini T. Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk! Medicina (Kaunas, Lithuania). 2023 Jun 17:59(6):. doi: 10.3390/medicina59061169. Epub 2023 Jun 17
[PubMed PMID: 37374373]
[30]
Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thrombosis research. 2006:118(4):523-8
[PubMed PMID: 16263154]
[31]
Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thrombosis and haemostasis. 2006 Nov:96(5):547-52
[PubMed PMID: 17080209]
[32]
Balandina AN, Serebriyskiy II, Poletaev AV, Polokhov DM, Gracheva MA, Koltsova EM, Vardanyan DM, Taranenko IA, Krylov AY, Urnova ES, Lobastov KV, Chernyakov AV, Shulutko EM, Momot AP, Shulutko AM, Ataullakhanov FI. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS one. 2018:13(6):e0199900. doi: 10.1371/journal.pone.0199900. Epub 2018 Jun 28
[PubMed PMID: 29953528]
[33]
Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. British journal of haematology. 1994 May:87(1):94-9
[PubMed PMID: 7947261]
[34]
Eschwège V, Seddiki S, Robert A. The tissue thromboplastin inhibition test in the detection of lupus anticoagulants: importance of a correction factor eliminating the influence of fibrinogen level. Thrombosis and haemostasis. 1996 Jul:76(1):65-8
[PubMed PMID: 8819253]
[35]
Gerbutavicius R, Fareed J, Messmore HL Jr, Iqbal O, Hoppensteadt DA, Wehrmacher WH, Demir M, Piccolo P, Ahmad S, Ma Q, Griniute R. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2002 Apr:8(2):115-24
[PubMed PMID: 12121051]
[36]
Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado MJ, Menegatti E, Erkan D, Roccatello D. Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clinical and molecular allergy : CMA. 2016:14():6. doi: 10.1186/s12948-016-0043-2. Epub 2016 Jul 15
[PubMed PMID: 27429595]
[37]
Radhakrishnan K. Kaolin clotting time. Methods in molecular biology (Clifton, N.J.). 2013:992():335-9. doi: 10.1007/978-1-62703-339-8_25. Epub
[PubMed PMID: 23546725]
[38]
Rosove MH, Ismail M, Koziol BJ, Runge A, Kasper CK. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood. 1986 Aug:68(2):472-8
[PubMed PMID: 3730611]
[39]
Dragoni F, Minotti C, Palumbo G, Faillace F, Redi R, Bongarzoni V, Avvisati G. As compared to kaolin clotting time, silica clotting time is a specific and sensitive automated method for detecting lupus anticoagulant. Thrombosis research. 2001 Jan 15:101(2):45-51
[PubMed PMID: 11342205]
[40]
Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. The Annals of thoracic surgery. 1996 Mar:61(3):795-9
[PubMed PMID: 8619695]
[41]
Radhakrishnan K. Platelet neutralization test. Methods in molecular biology (Clifton, N.J.). 2013:992():349-51. doi: 10.1007/978-1-62703-339-8_27. Epub
[PubMed PMID: 23546727]
[42]
Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. American journal of clinical pathology. 1983 Jun:79(6):678-82
[PubMed PMID: 6846258]
[43]
Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thrombosis and haemostasis. 1993 Nov 15:70(5):787-93
[PubMed PMID: 8128436]
[44]
Chandler JB, Torres R, Rinder HM, Tormey CA. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives. British journal of haematology. 2014 Dec:167(5):704-7. doi: 10.1111/bjh.13030. Epub 2014 Jul 18
[PubMed PMID: 25041401]
[45]
Moore GW. Mixing studies for lupus anticoagulant: mostly no, sometimes yes. Clinical chemistry and laboratory medicine. 2020 Mar 26:58(4):492-495. doi: 10.1515/cclm-2019-1248. Epub
[PubMed PMID: 31874095]
[46]
Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. Journal of thrombosis and haemostasis : JTH. 2020 Nov:18(11):2828-2839. doi: 10.1111/jth.15047. Epub
[PubMed PMID: 33462974]
[47]
Moore GW. Testing for Lupus Anticoagulants. Seminars in thrombosis and hemostasis. 2022 Sep:48(6):643-660. doi: 10.1055/s-0042-1744363. Epub 2022 Jun 1
[PubMed PMID: 35649428]
[48]
Talon L, Fourneyron V, Senectaire S, Tardieu M, Tillier M, Trapani A, Trayaud A, Vaissade A, Sapin AF, Lebreton A, Sinegre T. Lupus anticoagulant laboratory diagnosis by applying the 2020 ISTH-SSC guidelines. Thrombosis research. 2023 Apr:224():38-45. doi: 10.1016/j.thromres.2023.02.009. Epub 2023 Feb 18
[PubMed PMID: 36827954]
[49]
Chayoua W, Kelchtermans H, Moore GW, Musiał J, Wahl D, de Laat B, Devreese KMJ. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays. Journal of thrombosis and haemostasis : JTH. 2018 Oct:16(10):2016-2023. doi: 10.1111/jth.14261. Epub 2018 Aug 24
[PubMed PMID: 30079628]
[50]
Capecchi M, Abbattista M, Ciavarella A, Uhr M, Novembrino C, Martinelli I. Anticoagulant Therapy in Patients with Antiphospholipid Syndrome. Journal of clinical medicine. 2022 Nov 26:11(23):. doi: 10.3390/jcm11236984. Epub 2022 Nov 26
[PubMed PMID: 36498557]
[51]
Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 2013 Jan:22(1):18-25. doi: 10.1177/0961203312460722. Epub 2012 Sep 17
[PubMed PMID: 22988029]
[52]
Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. Journal of nephropathology. 2014 Jan:3(1):9-17. doi: 10.12860/jnp.2014.03. Epub 2014 Jan 1
[PubMed PMID: 24644537]
[53]
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D, ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis & rheumatology (Hoboken, N.J.). 2023 Oct:75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28
[PubMed PMID: 37635643]
[54]
Kornfehl A, Brock R, Staudinger T, Schellongowski P, Nagler B, Hermann A, Robak O, Schwameis M, Quehenberger P, Buchtele N. Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2023 Jan-Dec:29():10760296231207062. doi: 10.1177/10760296231207062. Epub
[PubMed PMID: 37853541]
[55]
Woo S, Kim B, Heo NH, Kim MS, Yoon YA, Choi YJ. Association of Lupus Anticoagulant status with Disease Course in SARS-CoV-2 (COVID-19) Infection. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2022 Jan-Dec:28():10760296221127276. doi: 10.1177/10760296221127276. Epub
[PubMed PMID: 36172745]
[56]
Favaloro EJ, Henry BM, Lippi G. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Seminars in thrombosis and hemostasis. 2022 Feb:48(1):55-71. doi: 10.1055/s-0041-1729856. Epub 2021 Jun 15
[PubMed PMID: 34130341]
[57]
Al-Ahmad M, Al Rasheed M, Altourah L, Rodriguez-Bouza T, Shalaby N. Lupus anticoagulant activity and thrombosis post COVID-19 vaccination. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2023 Jan 1:34(1):75-78. doi: 10.1097/MBC.0000000000001161. Epub 2022 Aug 9
[PubMed PMID: 35946452]
[58]
Pillai S, Calvert J, Fox E. Practical considerations for laboratories: Implementing a holistic quality management system. Frontiers in bioengineering and biotechnology. 2022:10():1040103. doi: 10.3389/fbioe.2022.1040103. Epub 2022 Nov 3
[PubMed PMID: 36406233]
Level 2 (mid-level) evidence
[59]
Carey RB, Bhattacharyya S, Kehl SC, Matukas LM, Pentella MA, Salfinger M, Schuetz AN. Practical Guidance for Clinical Microbiology Laboratories: Implementing a Quality Management System in the Medical Microbiology Laboratory. Clinical microbiology reviews. 2018 Jul:31(3):. doi: 10.1128/CMR.00062-17. Epub 2018 May 2
[PubMed PMID: 29720490]
Level 2 (mid-level) evidence
[60]
Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. Journal of clinical pathology. 2013 Dec:66(12):1027-32. doi: 10.1136/jclinpath-2013-201661. Epub 2013 Sep 26
[PubMed PMID: 24072731]
Level 2 (mid-level) evidence
[61]
Westgard JO. Internal quality control: planning and implementation strategies. Annals of clinical biochemistry. 2003 Nov:40(Pt 6):593-611
[PubMed PMID: 14629798]
Level 2 (mid-level) evidence
[62]
Kearney E. Internal quality control. Methods in molecular biology (Clifton, N.J.). 2013:1065():277-89. doi: 10.1007/978-1-62703-616-0_18. Epub
[PubMed PMID: 23996371]
Level 2 (mid-level) evidence
[63]
James D, Ames D, Lopez B, Still R, Simpson W, Twomey P. External quality assessment: best practice. Journal of clinical pathology. 2014 Aug:67(8):651-5. doi: 10.1136/jclinpath-2013-201621. Epub 2014 Mar 12
[PubMed PMID: 24621574]
Level 2 (mid-level) evidence
[64]
Kristensen GB, Meijer P. Interpretation of EQA results and EQA-based trouble shooting. Biochemia medica. 2017 Feb 15:27(1):49-62. doi: 10.11613/BM.2017.007. Epub
[PubMed PMID: 28392726]
[65]
Meisenhelder J, Bursik S, Lunn G, Strober W. Laboratory safety. Current protocols in human genetics. 2008 Apr:Appendix 2():Appendix 2A. doi: 10.1002/0471142905.hga02as57. Epub
[PubMed PMID: 18428418]
[66]
Asiry S, Ang LC. Laboratory Safety: Chemical and Physical Hazards. Methods in molecular biology (Clifton, N.J.). 2019:1897():243-252. doi: 10.1007/978-1-4939-8935-5_21. Epub
[PubMed PMID: 30539449]